Poxel Reports Cash Position, Financial Results for the Third Quarter 2015 and Provides Corporate Update Oct 22, 2015
Poxel Announces Upcoming Presentations on New Imeglimin Data at Two Key Scientific Conferences Oct 7, 2015
POXEL Raises EUR 20 Million in a Private Placement Led by Leading US Healthcare Investors Jul 24, 2015
Poxel’s Novel Anti-diabetic Agent Imeglimin Meets Glycemic Endpoints in Phase 2b Dose-Ranging Trial Jun 6, 2015
Poxel Announces Additional Positive Phase 2 Results Establishing Unique Glucose-Control Features of Imeglimin in Type 2 Diabetes Jun 4, 2015
POXEL Announces Successful Results for Imeglimin Phase 1 Study in Japanese Subjects and Appoints Dr. Yohjiro Itoh to Lead its Regulatory and Clinical Operations in Asia May 27, 2015
Noah D. Beerman Joins POXEL as Executive Vice President, Business Development and President, US Operations May 19, 2015
